A research team described an HDAC4-specific PROTAC degrader designed to enhance radiation therapy in lung cancer by boosting ferroptosis. The work centers on targeted protein degradation of histone-related functions tied to ferroptosis sensitivity, aiming to make radiotherapy more effective. The excerpt characterizes the study as a potential shift in combination oncology, pairing a degradation modality with standard-of-care radiation to overcome resistance mechanisms that often limit durable responses. If the preclinical effects translate, the program would strengthen the growing case for PROTACs as combination partners in radiosensitization strategies, particularly in tumor types where radiotherapy remains a key pillar of treatment.